Pfizer's Latest Immunotherapy Deal Could Be Great News for This Tiny Company – Motley Fool


Motley Fool

Pfizer’s Latest Immunotherapy Deal Could Be Great News for This Tiny Company
Motley Fool
While investors in this industry should hardly be surprised by speculative R&D deals, such agreements can provide clues as to which disease targets larger pharma companies are interested in before they go mainstream (see: CAR-T, CRISPR, etc).

and more »

Read More…

Share This: